Class: Immunosuppressive Agents
VA Class: IM600
Chemical Name: [3S[3R*,[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone monohydrate
Molecular Formula: C44H69NO12•H2O
CAS Number: 109581-93-3
Brands: Prograf
Warning
Use only under the supervision of a clinician experienced in immunosuppressive therapy and the management of organ transplant patients.
Patients should be managed in facilities with adequate laboratory and supportive medical resources; the clinician responsible for maintenance therapy should have complete information for patient follow-up.
Immunosuppression may result in increased susceptibility to infection and possible development of lymphoma or other neoplasms.
Introduction
Immunosuppressive agent.
Uses for Tacrolimus (Systemic)
Hepatic Allotransplantation
Prevention of hepatic allograft rejection; should be used in conjunction with corticosteroid therapy.
1-year graft and patient survival rates of approximately 73–88%.
Efficacy is comparable to that of a cyclosporine-based regimen in terms of 1-year patient and graft survival.
Renal Allotransplantation
Prevention of renal allograft rejection; should be used in conjunction with corticosteroid therapy.
1-year graft and patient survival rates of approximately 82–100%.
Efficacy is comparable to that of a cyclosporine-based regimen in terms of 1-year patient and graft survival.
Also has been used as “rescue” therapy† for acute or chronic renal ...
